SCHEMBL4151782

SCHEMBL4151782

CCCC(C)C(=O)NCC

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 2/20 0.46
HSD17B10 Q99714 3/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CNR1 P21554 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15314121 1.00 MAPK1 (0.51) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL22020057 0.86 CA1 (0.47) MAPK1LMNAMAPTCA1CA2
SCHEMBL9462495 0.84 LMNA (0.50) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL17210781 0.84 LMNA (0.50) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL17210780 0.84 LMNA (0.50) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL8275339 0.84 LMNA (0.39) MAPK1LMNAMAPTTSHRCA1
SCHEMBL9462565 0.82 MAPK1 (0.49) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL25086839 0.80 CYP2D6 (0.46) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL14894449 0.80 MAPK1 (0.47) MAPK1LMNAMAPTTSHRHSD17B10
SCHEMBL18125094 0.80 CNR1 (0.58) MAPK1LMNAMAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113473860-A 1, 3, 4-oxadiazoles and derivatives thereof as novel antifungal agents 拜耳公司 2021-10-01 CN disclosed
WO-2021125279-A1 CHEMICALLY CROSSLINKED ALGINATE GEL FIBER 持田製薬株式会社 2021-06-24 WO disclosed
EP-3385284-B1 ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-02-26 EP disclosed
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES BASF SE (DE) 2009-05-21 US disclosed
US-7235544-B2 for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES PRMT5, CYC1, CBR3 MAPK1 1958/4885LMNA 2037/4885MAPT 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.